Table 1.

Patient characteristics

	No.	Median (range)
Age (years)		54 (39–78)
Sex: Male/female	15 / 8
Race: Caucasian/Blacks	18 / 5
Isotype: Ig G/A/LC	11 / 4 / 8
No of Prior Regimens		7 (3–13)
SCT-Autologous/Tandem/Allo	20 / 6/ 1
Prior Thalidomide / Lenalidomide	23 / 17
Bortezomib	19
Duration (months)		6 (2–40)
No. of regimens 1/2/3	8 / 5 / 6
Primary refractory	9
Responsive then progressive	10
ECOG		1 (0–2)
Time from diagnosis to study (years)		5.7 (1.8 – 9)
Time from last therapy (days)		20 (15 –39)
Creatinine (mg/dl)		1.3 (0.7 – 2.1)
Hgb (g/dl)		11 (8.5 – 14)
Platelets (×103/ul)		148 (62 – 253)
Albumin (g/dl)		3.8 (2.5 –4.7)
LDH (Units/L)		209 (104 – 619)
Beta-2-microglobulin (mg/L)		3 (1.3 – 6)
Baseline Peripheral neuropathy	13
Grade 1 / 2	11 / 2
Abnormal karyotype	14
11;14	6
Hypodeploidy: del(13), del(17)	7/3
Dup, der, del(1)	9